Cellfe, Inc.
Alameda, CA Doing business as R&D
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1000 Atlantic Ave #104, Alameda, CA 94501, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Topic 397 - microfluidic transfection platform for rapid manufacturing of mrna car lymphocyte products. | National Cancer Institute (NIH) | $358,930 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Enrich Biosystems Inc. | Branford, CT | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Indee Labs | San Francisco, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Endomimetics, Inc. | Birmingham, AL | — |
| Proteios Technology, Inc. | Issaquah, WA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Desicorp, Inc. | Louisville, KY | 325414 Biological Product (except Diagnostic) Manufacturing |
About the company
Cellfe Inc. is a corporate entity registered in SAM.gov to receive federal contract and grant awards. Cellfe Inc. provides research and development services related to biomedical engineering and cell therapy manufacturing to federal agencies, primarily the National Institutes of Health.
Cellfe Inc. has received one prime SBIR Phase I federal contract from the National Cancer Institute for $358,930 to conduct research and development of a microfluidic transfection platform for rapid manufacturing of mRNA CAR lymphocyte products. This contract was awarded through a total small business set-aside under the SBIR program.
Cellfe Inc. has received three prime federal grants from the National Heart, Lung and Blood Institute. Two project grants worth $2,741,498 total were awarded to develop an efficient and scalable microfluidic gene delivery platform for genetic modification of hematopoietic stem cells to treat blood diseases. A third project grant worth $284,735 was awarded to develop a microfluidic platform for gene delivery into T-cells.
Quick answers
Is Cellfe, Inc. registered in SAM.gov?
Yes. Cellfe, Inc.'s SAM.gov registration is active through March 25, 2027.
What is Cellfe, Inc.'s CAGE code?
Cellfe, Inc.'s CAGE code is 80SL2, and its Unique Entity ID (UEI) is M34JNT47EKK3.
What is Cellfe, Inc.'s most recent federal award?
Cellfe, Inc.'s most recent federal grant award is Accelerated, scalable same-day microfluidic sequential gene editing for allogeneic cell therapy (R43GM161199), from National Institute of General Medical Sciences (NIH), on September 1, 2025.
On GovTribe
See Cellfe, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors